INmune Bio (Nasdaq: INMB), the Boca Raton, Florida-based clinical-stage biotechnology company, and Anthony Nolan, the UK stem cell charity, have signed an amended and restated Material Transfer and License Agreement to expand their existing collaboration centered on INmune Bio’s CORDStrom mesenchymal stromal cell platform. The restated agreement extends the scope of the partnership to cover recessive dystrophic epidermolysis bullosa, solid tumor oncology, and inflammatory and degenerative diseases including osteoarthritis and systemic lupus erythematosus. Financial terms were not disclosed.
Under the structure of the deal, Anthony Nolan’s Cell Therapy and Laboratory Services division supplies ethically sourced umbilical cord tissue meeting defined Materials Acceptance Criteria — including neonatal weight and maternal age specifications — while INmune Bio applies its proprietary downstream manufacturing workflow to convert that material into pooled, standardized MSC banks intended for off-the-shelf therapeutic use. The agreement covers supply and development activities subject to regulatory oversight by the FDA, EMA, and MHRA, with INmune Bio’s international and domestic entities both named as parties to the arrangement.
The CORDStrom platform uses umbilical cord-derived MSCs that are tested, screened, and pooled to generate standardized cell banks, a manufacturing approach INmune Bio positions as a solution to the donor variability and batch inconsistency that have historically complicated MSC-based therapy development. The platform is designed for supply across the UK, EU, US, and other global regions, and the expanded agreement with Anthony Nolan is intended to secure long-term access to the biological starting material that underpins that manufacturing model.